Western Wealth Management LLC purchased a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 5,629 shares of the company’s stock, valued at approximately $1,045,000.
A number of other large investors have also modified their holdings of the stock. Pearl River Capital LLC purchased a new stake in IDEXX Laboratories in the 4th quarter worth approximately $28,000. Sontag Advisory LLC purchased a new position in IDEXX Laboratories during the 4th quarter valued at about $79,000. Quantamental Technologies LLC purchased a new position in IDEXX Laboratories during the 4th quarter valued at about $92,000. Ipswich Investment Management Co. Inc. purchased a new position in IDEXX Laboratories during the 4th quarter valued at about $124,000. Finally, ETF Managers Group LLC boosted its holdings in IDEXX Laboratories by 15.8% during the 4th quarter. ETF Managers Group LLC now owns 682 shares of the company’s stock valued at $127,000 after acquiring an additional 93 shares during the period. Institutional investors own 88.27% of the company’s stock.
A number of equities analysts recently commented on IDXX shares. BidaskClub upgraded IDEXX Laboratories from a “sell” rating to a “hold” rating in a report on Thursday, January 24th. Zacks Investment Research upgraded IDEXX Laboratories from a “hold” rating to a “strong-buy” rating and set a $236.00 target price for the company in a report on Monday, February 4th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $246.00.
Shares of IDXX traded down $0.68 during midday trading on Monday, hitting $218.75. The company had a trading volume of 2,769 shares, compared to its average volume of 527,357. The stock has a market capitalization of $18.79 billion, a PE ratio of 51.33 and a beta of 0.97. IDEXX Laboratories, Inc. has a 1 year low of $176.11 and a 1 year high of $256.22.
IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Friday, February 1st. The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.90 by $0.08. The business had revenue of $549.39 million during the quarter, compared to analysts’ expectations of $546.04 million. IDEXX Laboratories had a negative return on equity of 1,501.97% and a net margin of 17.03%. The business’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.43 EPS. Research analysts forecast that IDEXX Laboratories, Inc. will post 4.69 EPS for the current fiscal year.
WARNING: This article was first reported by WKRB News and is the property of of WKRB News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.wkrb13.com/2019/03/25/western-wealth-management-llc-takes-1-05-million-position-in-idexx-laboratories-inc-idxx.html.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
Recommended Story: Momentum Investing
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.